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C A S E R E P O R T
Type B Insulin Resistance Masquerading
as Ovarian Hyperthecosis
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Robert Semple,2,3 and Phillip Gorden1
1National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda,
Maryland 20892; 2The University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC
Institute ofMetabolic Science, Cambridge CB2OQQ, United Kingdom; and 3TheNational Institute for Health
Research Cambridge Biomedical Research Centre, Cambridge CB2 OQQ, United Kingdom
Context: Hyperinsulinemia can lead to pathologic ovarian growth and androgen production.
Case Description: A 29-year-old woman developed an autoantibody to the insulin receptor (type B
insulin resistance), causing extreme insulin resistance and hyperinsulinemia. Testosterone levels were
elevated to the adultmale range. Treatmentwith gonadotropin-releasing hormone (GnRH) analog led
to normalization of testosterone, despite persistent extreme insulin resistance.
Conclusions: This case demonstrates that gonadotropins are necessary for insulin to cause path-
ologic ovarian androgen production. Suppression of gonadotropins with GnRH analogs may be a
useful therapeutic option in patients with severe hyperandrogenism or ovarian enlargement be-
cause of hyperinsulinemia. (J Clin Endocrinol Metab 102: 1789–1791, 2017)
Severe hyperandrogenism causing virilization inwomen is rare; causes include congenital adrenal
hyperplasia, adrenal or ovarian tumors, Cushing syn-
drome, and ovarian hyperthecosis. Ovarian hyperthecosis
is a rare disorder of severe, functional ovarian hyper-
androgenism, usually associatedwith insulin resistance (IR),
similar to polycystic ovarian syndrome (PCOS). Extreme
forms of IR, including lipodystrophy, mutations of the
insulin receptor, or autoantibodies to the insulin receptor
(type B IR), represent even more dramatic examples of IR
leading to functional ovarian hyperandrogenism, and may
be associated with massive ovarian enlargement and tes-
tosterone levels in the adult male range (1).
It was previously suggested that, in extreme IR, insulin
alone could lead to pathologic ovarian androgen pro-
duction, independent of gonadotropins (1). Here, we
present a case demonstrating that gonadotropins are re-
quired as cofactors for insulin-induced hyperandrogenism
in type B IR.
Case Presentation
A previously healthy 29-year-old African American
woman developed secondary amenorrhea, followed
8months later by polyuria, polydipsia, and 20-lb (9.1 kg)
weight loss. Blood glucose was 40 to 400 mg/dL; he-
moglobin A1c was 6.1%. She had symptoms of virili-
zation, including deepened voice, decreased breast size,
android body shape, acne, clitoromegaly, hirsutism, and
increased rage. Darkening of the skin occurred on the
face, axillae, elbows, and abdomen. Laboratory evalua-
tion revealedmarkedly elevated total and free testosterone
[total: 450 to 610 ng/dL (normal: 2 to 45 ng/dL), free:
25.6 pg/mL (normal: 0.2 to 5 pg/mL)]. Adrenal andro-
gens were normal [17-hydroxyprogesterone: 102 ng/dL
(normal,185 ng/dL), dehydroepiandrosterone sulfate:
84 mg/dL (normal: 40 to 325 mg/dL)]. Gonadotropins were
normal [luteinizing hormone (LH): 13.7 IU/mL, follicle-
stimulating hormone: 5.1 IU/mL]. Insulin-like growth
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factor 1was 100 ng/mL (normal: 117 to 329 ng/mL).Mild
pancytopenia was noted. Imaging showed bilaterally en-
larged ovaries with numerous follicles consistent with
PCOS, without masses; the adrenals appeared normal.
Because of the severity of the testosterone elevation, an
ovarian tumorwas suspected despite these imaging results.
Therefore, ovarian venous sampling was performed,
which showed testosterone .1500 ng/dL bilaterally.
The patient received a presumptive diagnosis of ovarian
hyperthecosis; leuprolide acetate depot injection 22.5 mg
intramuscularly was administered.
Three months after the leuprolide, the patient was evalu-
ated at theNational Institutes ofHealth after signing informed
consent under a natural history study of disorders of IR
(ClinicalTrials.gov no. NCT00001987), approved by the
Institutional Review Board of the National Institute of Di-
abetes and Digestive and Kidney Diseases. She reported im-
provedmood and skin tone, normal blood glucose except for
occasional fasting hypoglycemia, weight gain, and regression
of clitoromegaly. Examination revealed hirsutism and mild
acanthosis nigricans in the neck and malar distribution.
Testosterone was ,20 ng/dL, LH was 0.4 U/L, follicle-
stimulating hormone was 2.1 U/L, and fasting insulin was
29.3 mU/mL. Serum antibodies against the insulin receptor
were present (Fig. 1), confirming the diagnosis of type B IR.
Because the patient appeared to be entering spontaneous re-
mission, no treatment was given; it was not clear whether her
low testosteronewasattributable toher remissionor leuprolide.
At age 33 years, the patient returnedwithhyperglycemia
and hyperandrogenic symptoms. Hemoglobin A1c was
4.3% (falsely low because of active hemolysis), fasting
insulin was 279.6 mU/mL, and glucose was 122 mg/dL.
Anti-Smith/ribonucleoprotein antibody was .200 IU
(normal:,20), anti-nuclear antibodywas.12 IU (normal:
0 to 0.9 IU), anti-extractable nuclear antigens screen was
positive at.200 IU (normal: 0 to19 IU). Pancytopeniawas
noted. Testosterone was elevated at 777 ng/dL, with free
testosterone at 7.4 ng/dL (normal: 0.1 to 2.4 ng/dL). The
patient elected to defer immunosuppression for treatment
of type B IR, and instead received depot leuprolide acetate.
Two months later, total testosterone was 33.8 ng/dL (free
testosterone: 0.2 ng/dL). However, blood glucose was still
elevated at 182mg/dL, and fasting insulinwas143.7mU/mL.
Antibody depletion therapy with rituximab, pulsed dexa-
methasone, and oral cyclophosphamide was initiated as
previously described (2). Five months later, diabetes and IR
had resolved, menstrual periods had resumed, and total
testosterone was 45 ng/dL (normal: ,81 ng/dL).
Discussion
In this patient, a fortuitous missed diagnosis led to
the observation that gonadotropin suppression with
gonadotropin-releasing hormone (GnRH) analog could
effectively treat the hyperandrogenism (but not the di-
abetes) of type B IR. Although antibody depletion therapy
addresses the root cause of type B IR, thus ameliorating
both hyperandrogenism and diabetes (2), GnRH analogs
may be an alternative approach for patients who have
contraindications to immunosuppressive drugs, or are
unwilling to accept their side effects. Moreover, GnRH
analogs may be options for women with severe hyper-
androgenism caused by insulin receptor mutations, who
might otherwise require oophorectomy.
In 1975, Flier et al. (3) reported that, in 3 of 6 patients
with extreme IR, a serum factor (thought to be an anti-
body) was present that impaired insulin binding to its re-
ceptor. The waxing and waning nature of type B IR, with
spontaneous remissions and recurrences, and hyper- and
hypoglycemic manifestations, was described in 1978 (4).
Hyperandrogenism was not in the initial descriptions
of type B IR, but it was later recognized as a frequent
Figure 1. Anti-insulin receptor autoantibody assay. Anti-insulin
receptor autoantibodies are demonstrated by immunoprecipitation
of solubilized insulin receptors with, from left to right: the patient’s
serum at 1:5 and 1:50 dilutions, compared with negative (1:5
dilution) and positive (1:5 and 1:50 dilutions) controls, and the INSR
alone (10). For detection of endogenous anti-insulin receptor
antibodies, serum was first diluted 1 in 5 or 1 in 50 in phosphate-
buffered saline prior to incubation with an optimized concentration
of a crude preparation of recombinant human INSR (hINSR; a lysate
of CHO cells stably expressing human insulin receptor) in
immunoprecipitation buffer (2.52 g/L NaF, 8.92 g/L Na4P2O7,
100 mM HEPES, and 300 mM NaCl) for 4 hours at 2°C to 8°C with
gentle agitation. Antibodies were then captured using goat
antihuman IgG agarose beads (A3316, Sigma, Billerica, MA; 2 hours
at 2-8°C with gentle agitation). Unbound hINSR was washed away
with bead wash buffer (immunoprecipitation buffer as previously
mentioned with the addition of 10 mM EDTA, pH 8.0, and 0.2%
Triton-X 100) before reducing and fragmenting captured hINSR
using Laemmli buffer. Samples were resolved by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis on 8% Bis-Tris gels
before detection of hINSR beta subunit using hINSR beta subunit-
specific antibody (sc-711; Santa Cruz, Dallas, TX) by immunoblotting.
INSR, insulin receptor.
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feature (5). Although gonadotropins serve as normal
physiologic stimuli for ovarian growth and steroido-
genesis after puberty, insulin can act as a pathologic
growth factor and stimulator of sex steroid production.
The correlation between hyperinsulinemia and hyper-
androgenemia in women with PCOS was first noted
in 1980, but the direction of causality was not clear
(6). The mechanisms by which hyperinsulinemia leads
to androgen excess are complex (7). Both insulin and
IGF-1 receptors are present in ovary, but most of
insulin’s effects on steroidogenesis appear to be me-
diated through the insulin receptor. Insulin synergizes
with LH to upregulate CYP17, thereby increasing
testosterone production (7). In typical PCOS, there is
selective resistance to insulin downstream of the in-
sulin receptor in pathways regulating glucose, whereas
sensitivity to insulin’s effects to increase steroido-
genesis in granulosa and theca cells is maintained (7).
In patients with dysfunctional insulin receptors, in-
cluding type B IR or insulin receptor mutations, it is
not clear how insulin signals within the ovary to in-
crease androgen production because one would ex-
pect all pathways downstream of the insulin receptor
to be blocked. Furthermore, in rodents, selective in-
sulin receptor deletion in theca cells prevents hyper-
androgenism induced by hyperinsulinemia (8); however,
germline insulin receptor mutations in humans do result
in hyperandrogenism (9). It is possible that insulin signals
through hybrid insulin/IGF-1 receptors. Regardless of this
confusion, studies of patients with type B IR strongly
support a causal role for insulin in hyperandrogenism
because testosterone increases when insulin is elevated,
and normalizes when remission occurs and insulinemia
returns to normal (5).
A previous publication by our group suggested that
insulin was sufficient to cause pathologic ovarian en-
largement and steroidogenesis, independent of gonado-
tropins (1). This conclusion was based on 4 patients with
extreme IR who had LH #1 U/L, with either ovarian
enlargement, elevated testosterone, or both. Based on these
observations, it was thought that suppressing gonado-
tropins pharmacologically in patients with extreme IR
would not resolve insulin-induced hyperandrogenism. On
reviewing these cases, however, the 2 of these 4 patients
who had testosterone levels.2 standard deviations above
normal were clinically in puberty based on breast devel-
opment. Similarly, of 18 postpubertal women with type B
IR, 2 had elevated testosterone despite LH #1 U/L
(unpublished data). Thus, although these patients’
random LH levels were undetectable, they presumably
had sufficient LH pulsatility to stimulate ovarian ste-
roidogenesis. The current case demonstrates that, similar
to other disorders of excess ovarian androgen synthesis,
insulin-induced ovarian androgen excess requires the
presence of gonadotropins, and can be suppressed by
GnRH agonists.
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